FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to new imidazopyrazines of formula 
where Q1 and R1 have the values specified in the patent claim, and to their pharmaceutically acceptable salts showing IGF-1R enzyme inhibiting activity and applicable for treatment and/or prevention of various diseases and conditions which are sensitive to tyrosine kinase inhibition.
EFFECT: preparation of the compounds showing IGF-1R enzyme inhibiting activity.
27 cl, 294 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEINKINASE INHIBITORS | 2005 |
|
RU2379308C2 |
| 8-METHYL-1-PHENYLIMIDAZO[1,5-a]PYRAZINE COMPOUNDS | 2011 |
|
RU2560162C2 |
| IMIDAZOPYRAZINES | 2012 |
|
RU2600327C2 |
| IMIDAZOPIRASOTHINES AS PDE1 INHIBITORS | 2016 |
|
RU2712219C2 |
| UREA-SUBSTITUTED IMIDAZOQUINOLINE ETHERS | 2001 |
|
RU2302418C2 |
| HETEROARYL COMPOUNDS, COMPOSITIONS CONTAINING THEM AND METHODS OF TREATING WITH USE OF SUCH COMPOUNDS | 2007 |
|
RU2478635C2 |
| N-(2-CYANO HETEROCYCLYL)PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | 2014 |
|
RU2669922C2 |
| JAK KINASE-MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF APPLYING THEREOF | 2010 |
|
RU2529019C2 |
| METHOD FOR PREPARING 6-ALKYLIDENEPENEM DERIVATIVES | 2003 |
|
RU2317297C2 |
| HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | 2018 |
|
RU2797822C2 |
